A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.

Trial Profile

A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Palifosfamide (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PICASSO-3; PICASSO-III
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 12 Sep 2016 Primary endpoint (Overall survival) has not been met according to the results published in the Journal of Clinical Oncology.
    • 12 Sep 2016 Results published in the Journal of Clinical Oncology.
    • 26 Mar 2013 Status changed from active, no longer recruiting to discontinued, according to a ZIOPHARM Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top